Evidence map›Paper›PMID 32905824›Full record

ArticleToxicology2020

Microphysiological system modeling of ochratoxin A-associated nephrotoxicity.

Tomoki Imaoka, Jade Yang, Lu Wang, Matthew G McDonald, Zahra Afsharinejad, Theo K Bammler, Kirk Van Ness, Catherine K Yeung, Allan E Rettie, Jonathan Himmelfarb and 1 more

Open access · greenAbstract read
In one paragraph

Article in Toxicology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
5.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. TheAntioxidants (Basel, Switzerland) · 2022
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Tomoki ImaokaDepartment of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington, 98195, USA.
Jade YangDepartment of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington, 98195, USA.
Lu WangDepartment of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington, 98195, USA.
Matthew G McDonaldDepartment of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, Washington, 98195, USA.
Zahra AfsharinejadDepartment of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington, 98195, USA.
Theo K BammlerDepartment of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington, 98195, USA.
Kirk Van NessDepartment of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington, 98195, USA.
Catherine K YeungDepartment of Pharmacy, School of Pharmacy, University of Washington, Seattle Washington, 98195, USA; Kidney Research Institute, Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington, 98104, USA.
Allan E RettieDepartment of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, Washington, 98195, USA.
Jonathan HimmelfarbKidney Research Institute, Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington, 98104, USA.
Edward J KellyDepartment of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington, 98195, USA; Kidney Research Institute, Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington, 98104, USA. Electronic address: edkelly@uw.edu.
University of Washington · US

Funding

XENOBIOTIC BIOTRANSFORMATION AND DISPOSITIONP30ES007033 · NIEHS · UNIVERSITY OF WASHINGTON · PI Sheela Sathyanarayana · 1995 to 2026
$42.5M
Using iPSCs to model patient outcomes in nephrotic syndromeUH3TR000504 · NCATS · UNIVERSITY OF WASHINGTON · PI HIMMELFARB, JONATHAN · 2014 to 2016
$6.1M
Tissue Chip Data to the Microphysiology Systems Database (MPS-Db) Supplement to A Microphysiological System for Kidney Disease Modeling and Drug Efficacy TestingUH3TR002158 · NCATS · UNIVERSITY OF WASHINGTON · PI HIMMELFARB, JONATHAN · 2019 to 2021
$4.2M
A Microphysiological System for Kidney Disease Modeling and Drug Efficacy TestingUG3TR002158 · NCATS · UNIVERSITY OF WASHINGTON · PI HIMMELFARB, JONATHAN · 2017 to 2018
$2.9M
Modulation of drug transport at the renal proximal tubule by uremic solutes – implications in chronic kidney diseaseR01GM121354 · NIGMS · UNIVERSITY OF WASHINGTON · PI YEUNG, CATHERINE K. · 2017 to 2021
$1.5M
CKDu and Ochratoxin-A: risk assessment studies in a microphysiological systemR21ES031359 · NIEHS · UNIVERSITY OF WASHINGTON · PI KELLY, EDWARD J · 2020 to 2021
$404k
EPA R835738EPA R835738C002NCATS NIH HHS UG3 TR002158NCATS NIH HHS UH3 TR000504NCATS NIH HHS UH3 TR002158NIEHS NIH HHS P30 ES007033NIEHS NIH HHS R21 ES031359NIGMS NIH HHS R01 GM121354
6 · The paper itself

Abstract

Ochratoxin A (OTA) is one of the most abundant mycotoxin contaminants in food stuffs and possesses carcinogenic, nephrotoxic, teratogenic, and immunotoxic properties. Specifically, a major concern is severe nephrotoxicity, which is characterized by degeneration of epithelial cells of the proximal tubules and interstitial fibrosis. However, the mechanism of OTA toxicity, as well as the genetic risk factors contributing to its toxicity in humans has been elusive due to the lack of adequate models that fully recapitulate human kidney function in vitro. The present study attempts to evaluate dose-response relationships, identify the contribution of active transport proteins that govern the renal disposition of OTA, and determine the role of metabolism in the bioactivation and detoxification of OTA using a 3D human kidney proximal tubule microphysiological system (kidney MPS). We demonstrated that LC

Indexed as

Models, BiologicalDose-Response Relationship, DrugEpithelial CellsHumansKidney DiseasesKidney Tubules, ProximalOchratoxinsochratoxin AOchratoxinsGSTsMicrophysiological systemsNephrotoxicityOchratoxin AOxidative stressProximal tubule epithelial cells

Identifiers

PMID32905824
PMCPMC7560959
OpenAlexW3083392211

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.